Anixa Biosciences with ticker code (ANIX) now have 2 analysts covering the stock. The analyst consensus points to a rating of ‘Buy’. The target price ranges between 9 and 8.5 calculating the mean target price we have 8.75. Now with the previous closing price of 5.25 this is indicating there is a potential upside of 66.7%. The 50 day moving average now sits at 4.09 and the 200 day moving average is 2.84. The market capitalisation for the company is $143m. Visit the company website at: http://www.anixa.com
Anixa Biosciences, a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company’s therapeutics programs include the development of a chimeric endocrine receptor T-cell technology, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer; and the discovery and development of anti-viral drug candidates for the treatment of COVID-19 focused on inhibiting certain viral protein functions of the virus. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. It has a collaboration agreement with OntoChem GmbH to discover and develop anti-viral drug candidates against COVID-19. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences in October 2018. Anixa Biosciences was founded in 1982 and is based in San Jose, California.